



GOVERNMENT OF PAKISTAN
(CABINET DIVISION)
INTELLECTUAL PROPERTY ORGANIZATION
THE PATENT OFFICE
KARACHI



To,

Dated: **01-09-2008**

Mr. Yasin Tahir,
Director General, IPO-Pakistan
Islamabad.

**Subject: WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE
WEEKENDING 23-8-2008 TO BE PUBLISHED 02-09-2008 IN THE
GAZETTE OF PAKISTAN PART-V.**

Sir,

Reference to IPO letter dated 12-5-2008 forwarding therewith copy of letter No 18/IPO/2008/ RA-IV dated 23-4-2008 from Cabinet Division on the above subject.

A manuscript copies of the weekly notification regarding application filed, application accepted and sealing fee due is enclosed herewith for onward transmission to the Cabinet Division for Publication in the next issue of the Gazette of Pakistan (Part –V)

(SABIR GUL)
ASSISTANT CONTROLLER OF PATENTS
Tel: 9215056

ENCL:

GOVERNMENT OF PAKISTAN
THE PATENT OFFICE
2nd Floor, Kandawala Building,
M.A. Jinnah Road,

Karachi

No.2/2/2003-F.Sec.

Dated: **01-09-2008**

To,

Mr. Manzoor Ahmed
Section Officer
Cabinet Secretariat
Cabinet Division
Government of Pakistan
Islamabad

**Subject: WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE
WEEKENDING 23-8-2008 TO BE PUBLISHED 02-09-2008 IN THE
GAZETTE OF PAKISTAN PART-V.**

Reference to Cabinet Secretariats letter No. 18/IPO/2008/RA-IV, dated 23rd April 2008. A manuscript copy of the weekly notification regarding application filed, application accepted and sealing fee due etc., is enclosed herewith for onward transmission to the Printing Corporation of Pakistan Press for publication in the next issue of the Gazette of Pakistan Part-V.

(SABIR GUL)
ASSISTANT CONTROLLER OF PATENTS
Tel: 9215056

ENCL:

NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

996/2008	<u>18-8-2008</u> Glaxo Group Limited, UK (Priority 20-08-07 USA)	“Novel cathepsin c inhibitors and their use”
997/2008	<u>19-8-2008</u> Arena Pharmaceuticals, Inc., U.S.A. (Priority 23-12-2004 USA) DIVISIONAL	“Fused pyrazole derivatives and method of treatment of metabolic-related disorders thereof”
998/2008	1. Shahina Fayyaz 2. Tabassum Ara Khanum 3. Asim Rehan Kazmi. Karachi/Pakistan.	“Use of three microtermis spp. (isoptera: rhinonematidae)”
999/2008	Oncotherapy Science, Inc., Japan. (Priority 20-08-2007 Japan)	“Cdh3 peptides and agents comprising the same”
1000/2008	Syngenta Limited., United Kingdom (Priority 24-08-2007 GB)	“Improvements in or relating to organic compounds”
1001/2008	Syngenta Limited, United Kingdom (Priority 24-08-2007 GB)	“Improvements in or relating to organic compounds”
1002/2008	<u>20-8-2008</u> Syngenta Participations AG, Switzerland (Priority 20-08-2007 U.K.)	“Novel insecticides”
1003/2008	Huawei Technologies Co., Ltd. China (Priority 20-08-2007 China)	“Sip-based user registration method, system, terminal, and server”

	<u>21-8-2008</u>	
1004/2008	Astrazeneca AB, Sweden. (Priority 22-08-2007 USA)	“Cyclopropyl amide derivatives 978”
1005/2008	Sanofi-Aventis, France. (Priority 23-08-2007 E.P)	“Azoloarine derivatives, process for their preparation, medicaments comprising these compounds and their use”
	<u>22-8-2008</u>	
1006/2008	F. Hoffmann-LA Roch AG., Switzerland. (Priority 16-12-1999 USA) DIVISIONAL	“A process for the preparation of substituted bisindolylmaleimide”
1007/2008	POSCO, Korea. (Priority 24-08-2007 Korea)	“Coating composition for steel sheets having zinc and zinc alloy coating layer, method for forming coating layer using the coating composition and steel sheet having the coating layer formed thereof”
1008/2008	Eli Lilly and Company, USA. (Priority 21-11-1996 USA) DIVISIONAL	“A process for the preparation of an alkylated glycopeptide antibiotic”
1009/2008	Novartis AG., Switzerland. (Priority 24-08-2007 E.P)	“Organic Compounds”
1010/2008	Irmlic, Bermuda. (Priority 22-08-2007 USA)	“Compounds and compositions as kinase inhibitors”
	<u>23-8-2008</u>	
1011/2008	1.Zahida N. Umer. 2.Muhammad Kamran 3.Nida Saleem Karachi/Pakistan.	“A process for the production of sweetbanana chips and its by products”
1012/2008	Aleksejs Safronovs, Latvia. (Priority 12-09-2007 Latvia)	“Method for compressing gaseous fuel for fueling vehicle and device for implementation thereof”

1013/2008	N.V. Organon, Netherland. (Priority 31-08-2007 Europe)	“TSH receptor antagonizing tetrahydroquinoline compounds”
1014/2008	1.Musarrat Akhter. 2.Hanif A. Khan. 3.M. Salih Solangi. 4. Khaula Shirin 5.Askari Bequm. P.C.S.I.R. Karachi	“A process for the production of biological nematicide for the control of plant parasitic nematodes attacking banana plantation (Mussa Spp.) form indigenous material”
1015/2008	1.Mr. LI SHU M/s. Plum Qingqi Motors, Limited. Lahore/Pakistan	“Box differential & Reverse System”
1016/2008	1.Mr. LI SHU, M/s. Plum Qingqi Motors, Limited. Lahore/Pakistan	“Air Gas Mixer”
1017/2008	1.Mr. LI SHU, M/s. Plum Qingqi Motors, Limited. Lahore/Pakistan	“For forced air cooling system”
1018/2008	Novartis AG., Switzerland. (Priority 23-08-2007 E.P)	“Aminobenzyl-substituted cyclic sulfones useful as BACE inhibitors”
1019/2008	Dr. Pieter Huybers, Netherlands. (Priority 17-03-2008 E.P)	“A new kind of football with improved roundness”

~~~~~

## APPLICATION ACCEPTED

Notice is hereby given that the person interested in opposing the grant of Patents to any of the applications referred to below at any time within four months from the date of this Gazette may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules 18(1) of 2003.

The six figures number shown in the right hand side are those given to applications on acceptance of the complete specification under which the specification will be printed and subsequent proceeding taken.

The figures shown within square brackets after the title of inventions indicate their classification index at acceptance.

Typed copies of the specification which are to open to public inspection can be supplied by the Patent Office on payment of the prescribed charges which may be ascertained on application to the office.

570/1998


Novartis AG,  
Switzerland.

“A crystal modification of a pharmaceutically active compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide”

(A61K, 31/4192)

**139718**

The invention relates to the novel modification A or A' of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide of the formula



Its use and pharmaceutical composition comprising this crystal modification.

863/2002


E.I. DU Pont  
DE Nemours  
and Company,  
USA.

“An iminobenzoxazine compound”

(A01N, 43/86)

**139719**

This invention pertains to methods for controlling invertebrate pests comprising contacting the invertebrate pest or its environment with a biologically effective amount of a compound of Formula I



wherein

B is O, S or NR<sup>1</sup>;

J is a phenyl ring, a naphthyl ring system, a 5- or 6-membered heteroaromatic ring or an aromatic 8-, 9- or 10-membered fused heterobicyclic ring system wherein each ring or ring system is optionally substituted with 1 to 4 R<sup>5</sup>; and R<sup>1</sup>, R<sup>2</sup>, R<sup>4</sup>, R<sup>3</sup> and n are as defined in the disclosure.

This invention also pertains to certain compounds of Formula I and compositions for controlling invertebrate pests comprising a biologically effective amount of a compound of Formula I and at least one additional component selected from the group consisting of surfactants, solid diluents and liquid diluents and optionally further comprising an effective amount of at least one additional biologically active compound or agent.

1008/2002

Menarini  
International  
Operations  
Luxembourg  
S.A,  
Luxembourg.

“A pharmaceutical composition comprising glibenclamide and metformin”

(A61K, 9/20, 31/64)


**139720**

Orally administrate pharmaceutical compositions in the form of tablets, comprising glibenclamide and metformin, or pharmaceutically acceptable salts thereof, as active ingredients, maintained separate from one another within the same composition, are described for the treatment of type-II diabetes mellitus.

919/2003

Sumitomo  
Chemical  
Company,  
Limited,  
Japan.

“1,2,4-thiadiazole compound”



(CO7D, 285/08, AO1N, 43/836)

**139721**

The present invention relates to a novel 1,2,4-thiadiazole compound represented by the formula (1):

wherein, R<sup>1</sup> represents C3-C7 alkynyl that may be substituted with halogen; R<sup>2</sup> represents C3-C8 cycloalkyl which may be substituted with C1-C4 alkyl, halogen atom and trifluoromethyl or the like; A<sup>1</sup> represents a single bond, C1-C2 alkylene or C2-C3 alkylidene.

The 1,2,4-thiadiazole compound has an excellent arthropod controlling activity, and can effectively control an arthropod pests such as insect pests, acarine pests and the like.

14/2004


E.I.Du Pont DE  
Nemours and  
Company.  
USA.

“A cyano anthranilamide compound”

(AO1N, 43/56)

**139722**

This invention provides compound of Formula 1, N-oxides



wherein

R<sup>1</sup> is Me, Cl, Br or F;

R<sup>2</sup> is F, Cl, Br, C<sub>1</sub>-C<sub>4</sub> haloalkyl or C<sub>1</sub>-C<sub>4</sub> haloalkoxy;

R<sup>3</sup> is F, Cl or Br;

R<sup>4</sup> is H; C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>3</sub>-C<sub>4</sub> alkenyl, C<sub>3</sub>-C<sub>4</sub> alkynyl, C<sub>3</sub>-C<sub>5</sub> cycloalkyl, or C<sub>4</sub>-C<sub>6</sub> cycloalkylalkyl, each optionally substituted with one substituent selected from the group consisting of halogen, CN, SMe, S(O)Me, S(O)<sub>2</sub>Me, and OMe;

R<sup>5</sup> is H or Me;

R<sup>6</sup> is H, F or Cl; and

R<sup>7</sup> is H, F or Cl.

Also disclosed are methods for controlling an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of a compound of Formula 1, an N-oxide thereof or the compound (e.g., as a composition described herein). This invention also pertains to a composition for controlling an invertebrate pest comprising a biologically effective amount of a compound of Formula 1, an N-oxide thereof and at least one additional component selected from the group consisting of a surfactant, a solid diluent and a liquid diluent.

124/2004

Syngenta  
Participations  
AG,  
Switzerland.

“A suspoemulsion composition comprising 2-(substituted benzoyl)-1,3-cyclohexanedio-NE”

(AOIN, 25/04, 41/10)

139723

A suspoemulsion formulation comprising:

- (a) a continuous phase comprising
  - (i) one or more block co-polymers, and
  - (ii) one or more non-ionic surfactants;
- (b) a dispersed emulsion phase comprising
  - (i), a chloroacetamide, and
  - (ii) a polymeric stabiliser; and
- (c) a dispersed solid phase comprising
  - (i) a 2-(substituted benzoyl)-1,3-cyclohexanedione herbicide; and
  - (ii) a stabilising metal salt.

521/2004


Glaxo Group  
Limited,  
United  
Kingdom.

“6 $\alpha$ , 9 $\alpha$ -difluoro-11 $\beta$ -hydroxy-16 $\alpha$ -methyl-3-oxo-17 $\alpha$ -(2,2,3,3-tetramethylcyclopropyl-carbonyl)oxy-androsta-1, 4-diene-17 $\beta$ -carboxylic acid cyanomethyl ester”

(CO7D, 215/86)

139724

A compound of formula (I):



or a physiologically acceptable solvate thereof.

828/2004

Smithkline  
Beecham  
Corporation,  
USA.

“2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3’-(1H-tetrazol-5-yl)biphenyl-3-yl]hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline”

(A61K, 31/41, CO7D, 257/04)

**139725**

An improved thrombopoietin mimetic, the choline salt of 2-(3,4-dimethylphenyl)-4-[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-one.

917/2004

Boehringer  
Ingelheim  
International  
GmbH,  
Germany.

“A pharmaceutical composition comprising monoamine”

(A61K, 31/46)

**139726**

The invention relates to a solid pharmaceutical preparation containing one or more solid carriers and/or excipients and an active substance selected from among the Monoamine Neurotransmitter Re-uptake Inhibitors which have a 2,3-disubstituted tropane structure, the preparation thereof and use thereof for preparing a pharmaceutical composition for the treatment or prevention of central-nervous diseases or disorders.

101/2005


Smithkline  
Beecham  
Corporation,  
USA.

“Novel xanthine compound and composition containing it”

(CO7D, 471/02)

**139727**

The present invention provides therapeutically active compound which are xanthine compound, process for the manufacture of said compound, pharmaceutical composition containing the active compound and the use of the compound in therapy, particularly in /treatment of diseases where under-activation of the HM74A receptor contributes to the (ease or where activation of the receptor will be beneficial, having the formula (II):



wherein

R<sup>1</sup> is selected from: hydrogen and C1-4 alkyl which may be optionally substituted with one or more groups selected from CN and CF<sub>3</sub>,

R<sup>2</sup> is selected from: C<sub>2-10</sub> unsubstituted alkyl, CMO alkyl substituted with one or more groups selected from fluorine and CN, C<sub>5</sub> alkenyl, unbranched C<sub>4</sub> alkenyl, and C<sub>1-4</sub> alkyl substituted with cycloalkyl,

and R<sup>3</sup> is selected from halogen and CN.

282/2005

DSM IP Assets  
B.V.,  
Netherlands.

“Urea granules process”

(CO5B, 19/00)

**139728**

Urea granulation process in a granulator that contains urea nuclei, to which a urea melt and at least one granulation additive are added, wherein the urea nuclei are transported and the urea melt is added perpendicularly to the direction of transport of the urea nuclei, wherein the granulation additive is at least partially supplied to the last section of the granulator.

957/2005


Syngenta  
Participations  
AG.  
United  
Kingdom.

“A novel anthranilamide compound and process of its preparation”

A01N 31/04, A01N 41/12, CO7DC 381/08

**139729**

Compound of formula I.



wherein the substituents are as defined in claim 1, and the agrochemically acceptable salt and all stereoisomer and tautomeric forms of the compound of formula I can be used as agrochemical active ingredients and can be prepared in a manner known per se.

92/2008


SmithKline  
Beecham  
Corporation.  
USA.

“Novel xanthine compound, composition containing it and its use in therapy”

CO7D 213/00

**139730**

The present invention provides therapeutically active compounds which are xanthine derivative, process for the manufacture of said derivative, pharmaceutical composition containing the active compound and the use of the compounds in therapy, particularly in the treatment of diseases where under-activation of the HM74A receptor contributes to the disease or where activation of the receptor will be beneficial, having the formula (II):



Wherein

$R^1$  is selected from: hydrogen and  $C_{1-4}$  alkyl which may be optionally substituted with one or more groups selected from CN and  $CF_3$ ,

$R^2$  is selected from:  $C_{2-10}$  unsubstituted alkyl,  $C_{1-10}$  alkyl substituted with one or more groups selected from fluorine and CN,  $C_5$  alkenyl, unbranched  $C_4$  alkenyl, and  $C_{1-4}$  alkyl substituted with cycloalkyl,

And  $R^3$  is selected from halogen and CN.

☒☒☒☒☒

**(SABIR GUL)**  
ASSISTANT CONTROLLER OF PATENTS  
Tel: 9215056